VORVor Biopharma Inc.
$19.16-43% 1Y
$19.16
$6.8652 weeks$33.40
VOR in its own filings
VOR's filing record carries one kind of hard flag, each is shown beside the share of the whole market carrying the same one, because more than half of all companies carry at least one.
105
Events found in the filings · across 459 filings · the record starts in 2020
- Hard flags
- 1
Hard flags
- Most recent filing
- Aug 11, 2026
Most recent filing · Form 10-Q
- Record starts
- Dec 4, 2020
Record starts · the earliest filing Ryufin holds for this name
Details›
- Delisting notice / listing-rule failure2 occurrences
- 2025-04-25
- SEC comment-letter activity21 occurrences
- 2026-05-04
SEC EDGAR submissions index and 8-K item codes; 4.02 and 1.03 items are confirmed against the filing text.
What the company said
The company's own words from its current reports to the SEC, newest first
- Jul 7, 2026Resignation of Andrew Levin, M.D., Ph.D. as a Director On July 6, 2026, Andrew Levin, M.D., Ph.D., a member of the Board of Directors (the “Board”) of Vor Biopharma Inc. (the “Company”), delivered his notice of resignation, effective immediately.Director or officer change · Form 8-K
- Jun 8, 2026Telitacicept Receives NMPA Conditional Approval for the Treatment of IgA Nephropathy in China.Regulation FD disclosure · press release
- Mar 27, 2026On March 26, 2026, Vor Biopharma Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with entities affiliated with TCGX (the “Investors”) pursuant to which the Company, in a private placement, agreed to issue and sell to the Investors an aggregate of 5,338,078 shares (the …Material agreement entered · Form 8-K
- Jan 12, 2026Global Science. One Purpose. 44th Annual J.P. Morgan Healthcare Conference January 2026.Earnings release · press release
- Jan 2, 2026On December 31, 2025, Vor Biopharma Inc. (the “Company”) entered into a separation agreement (the “Separation Agreement”) with Dr. Qing Zuraw, the Company’s Chief Development Officer, as a result of Dr. Zuraw’s decision to pursue other opportunities.Director or officer change · Form 8-K
- Dec 18, 2025On December 15, 2025, Vor Biopharma Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with certain investors (the “Investors”) pursuant to which the Company, in a private placement, agreed to issue and sell to the Investors an aggregate of 13,876,032 shares (the “Shares”) of …Material agreement entered · Form 8-K
- Dec 9, 2025On December 5, 2025 (the “Effective Date”), the board of directors (the “Board”) of Vor Biopharma Inc. (the “Company”) approved a stock option repricing whereby the exercise price of certain outstanding options to purchase shares of the Company’s common stock (the “Common Stock”) under the Company’s Amended and …Director or officer change · Form 8-K
- Nov 12, 2025On November 10, 2025, Vor Biopharma Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with J.P. Morgan Securities LLC, Jefferies LLC, Citigroup Global Markets Inc. and TD Securities (USA) LLC, as representatives of the several underwriters named therein (collectively, the …Other event · Form 8-K
- Nov 3, 2025On November 2, 2025 (the “Effective Date”), Vor Biopharma Inc. (the “Company”) and Dr. Qing Zuraw, the Company’s Chief Development Officer, entered into an amendment (the “Employment Agreement Amendment”) to Dr. Zuraw’s employment agreement with the Company dated July 17, 2025 (the “Employment Agreement”)Director or officer change · Form 8-K
- Oct 28, 2025Global Science. One Purpose. 48-week Phase 3 Clinical Trial Data from China for Telitacicept in Primary Sjögren’s Disease October 28, 2025.Regulation FD disclosure · press release
- Sep 17, 2025The information contained in.Shareholder rights modified · Form 8-K
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
opening the record…